[go: up one dir, main page]

MX2009003794A - Composicion de prostaglandina e estabilizada. - Google Patents

Composicion de prostaglandina e estabilizada.

Info

Publication number
MX2009003794A
MX2009003794A MX2009003794A MX2009003794A MX2009003794A MX 2009003794 A MX2009003794 A MX 2009003794A MX 2009003794 A MX2009003794 A MX 2009003794A MX 2009003794 A MX2009003794 A MX 2009003794A MX 2009003794 A MX2009003794 A MX 2009003794A
Authority
MX
Mexico
Prior art keywords
prostaglandin
composition
alkyl
carboxylic ester
alcohols
Prior art date
Application number
MX2009003794A
Other languages
English (en)
Inventor
Daniel W Frank
Yiping Wang
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of MX2009003794A publication Critical patent/MX2009003794A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición de prostaglandina E sustancialmente libre de alcoholes (C1-C4) e incluye el compuesto de prostaglandina E junto con un éster carboxílico (C1-C4)-alquilo (C8-C22) (por ejemplo, laurato de etilo), un alquilamino N,N-di(C1-C9) sustituido, éster carboxílico (C4-C18) alquilo (C2-C18) y/o una sal de adición farmacéuticamente aceptable de las mismas y, de manera opcional, un agente que intensifica la viscosidad tal como goma guar. La composición de la prostaglandina E puede ser combinada con un diluyente alcohólico acuoso para formar una composición farmacéutica para aplicación tópica a un paciente, por ejemplo, para tratar disfunción sexual. Las composiciones de prostaglandina E son estables durante periodos prolongados de almacenamiento a temperatura ambiente.
MX2009003794A 2006-10-11 2007-10-05 Composicion de prostaglandina e estabilizada. MX2009003794A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/546,196 US7560489B2 (en) 2006-10-11 2006-10-11 Stabilized prostaglandin E composition
PCT/US2007/021374 WO2008045309A1 (en) 2006-10-11 2007-10-05 Stabilized prostaglandin e composition

Publications (1)

Publication Number Publication Date
MX2009003794A true MX2009003794A (es) 2009-04-24

Family

ID=39283156

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003794A MX2009003794A (es) 2006-10-11 2007-10-05 Composicion de prostaglandina e estabilizada.

Country Status (12)

Country Link
US (1) US7560489B2 (es)
EP (1) EP2073634A4 (es)
JP (1) JP5382800B2 (es)
KR (1) KR101400359B1 (es)
AU (1) AU2007307136B2 (es)
BR (1) BRPI0719228A2 (es)
CA (1) CA2665611C (es)
IL (1) IL197885A (es)
MX (1) MX2009003794A (es)
NZ (1) NZ576242A (es)
WO (1) WO2008045309A1 (es)
ZA (1) ZA200902467B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
US9220701B2 (en) 2008-10-03 2015-12-29 Nexmed Holdings, Inc. Stabilized composition for treating psoriasis
KR101429881B1 (ko) 2009-06-03 2014-08-13 포사이트 비젼4, 인크. 전안부 약물 전달
MX2012012824A (es) 2010-05-04 2013-07-03 Nexmed Holdings Inc Composiciones de productos terapeuticos de moleculas pequeñas.
KR20130067266A (ko) * 2010-05-04 2013-06-21 넥스메드 홀딩스 인코포레이티드 치료용 펩타이드 조성물 및 방법
CA2745320A1 (en) * 2011-07-06 2013-01-06 Duoject Medical Systems Inc. Reconstitution device
WO2013040426A2 (en) 2011-09-14 2013-03-21 Forsight Labs, Llc Ocular insert apparatus and methods
RU2652063C2 (ru) 2012-10-26 2018-04-24 Форсайт Вижн5, Инк. Офтальмологическая система для замедленного высвобождения лекарственного средства в глазу
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036954A (en) * 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
US4113882A (en) * 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
JPS58134019A (ja) * 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
US4806354A (en) * 1984-04-06 1989-02-21 Green James P Health food composition
US5525348A (en) * 1989-11-02 1996-06-11 Sts Biopolymers, Inc. Coating compositions comprising pharmaceutical agents
CA2071137A1 (en) * 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6825234B2 (en) * 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6693135B2 (en) * 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US20040110843A1 (en) * 2000-01-10 2004-06-10 Nexmed (Holdings), Inc. Methods of treatment of male erectile dysfunction
GB2372213B (en) * 2000-11-17 2003-07-16 Icebella Enterpises Ltd Applicator and stimulator device
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
DE602004007315D1 (de) * 2003-03-03 2007-08-16 Personnes A Responsibilite Lim Stabilisierte pharmazeutische Zusammensetzung enthaltend einen NSAID und einen Prostaglandin
AR043476A1 (es) * 2004-09-09 2005-08-03 Dvoskin Victor Oscar Dispositivo de administracion regulada de sustancias para la insercion en una cavidad corporal y procedimiento para fabricar un medio de soporte de dichas sustancias
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition

Also Published As

Publication number Publication date
AU2007307136B2 (en) 2013-12-05
JP5382800B2 (ja) 2014-01-08
AU2007307136A1 (en) 2008-04-17
EP2073634A4 (en) 2012-12-19
US7560489B2 (en) 2009-07-14
IL197885A0 (en) 2009-12-24
EP2073634A1 (en) 2009-07-01
KR20090064597A (ko) 2009-06-19
CA2665611C (en) 2014-11-25
IL197885A (en) 2016-04-21
JP2010506831A (ja) 2010-03-04
BRPI0719228A2 (pt) 2015-02-03
ZA200902467B (en) 2010-03-31
US20080090911A1 (en) 2008-04-17
WO2008045309A1 (en) 2008-04-17
CA2665611A1 (en) 2008-04-17
KR101400359B1 (ko) 2014-06-19
NZ576242A (en) 2012-04-27

Similar Documents

Publication Publication Date Title
MX2009003794A (es) Composicion de prostaglandina e estabilizada.
CA2757418C (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
TN2011000346A1 (en) Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
WO2008030744A3 (en) Inhibitors of c-met and uses thereof
PE20130236A1 (es) Composicion farmaceutica que comprende un derivado de amida o una sal farmaceuticamente aceptable del mismo
MX2011012628A (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
WO2012071389A3 (en) Stable cannabinoid compositions and methods for making and storing them
JO2852B1 (en) Anti-cancer compounds and pharmaceutical compositions
MY151295A (en) Pyrimidyl indoline compound
DK2041133T3 (da) Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik
BR112013030939A2 (pt) derivado de indazol e pirrolopiridina e uso farmacêutico do mesmo
WO2008143240A1 (ja) 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
MX2020008173A (es) Combinacion de un agente antimuscarinico o de uno anticolinergico y acido lipoico, y sus usos.
TN2013000257A1 (en) Immunosuppressant formulations
MX2009011554A (es) Preparacion solida estable conteniendo un derivado de 4,5-epoximorfinano.
MY155938A (en) Oral pharmaceutical composition
IN2012DN02502A (es)
MX2015017879A (es) Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa.
PH12015500864A1 (en) Liquid formulation comprising gm-csf neutralizing compound
AU2015275248B2 (en) Legumain activated doxorubicin derivative as well as preparation method and application thereof

Legal Events

Date Code Title Description
FG Grant or registration